JP2012167125A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012167125A5 JP2012167125A5 JP2012131109A JP2012131109A JP2012167125A5 JP 2012167125 A5 JP2012167125 A5 JP 2012167125A5 JP 2012131109 A JP2012131109 A JP 2012131109A JP 2012131109 A JP2012131109 A JP 2012131109A JP 2012167125 A5 JP2012167125 A5 JP 2012167125A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- phenyl
- capsule
- diazaspiro
- decan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 16
- 239000002775 capsule Substances 0.000 claims 13
- 238000009472 formulation Methods 0.000 claims 13
- -1 3,5-bis- (trifluoromethyl) phenyl Chemical group 0.000 claims 7
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 claims 7
- DTYVGTMMVDMEFH-UHFFFAOYSA-N 1,9-diazaspiro[4.5]decan-2-one Chemical compound N1C(=O)CCC11CNCCC1 DTYVGTMMVDMEFH-UHFFFAOYSA-N 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 229940127089 cytotoxic agent Drugs 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010028813 Nausea Diseases 0.000 claims 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical group O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 2
- 206010047700 Vomiting Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- ZAJNGDIORYACQU-UHFFFAOYSA-N decan-2-one Chemical compound CCCCCCCCC(C)=O ZAJNGDIORYACQU-UHFFFAOYSA-N 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 230000008693 nausea Effects 0.000 claims 2
- 229960004964 temozolomide Drugs 0.000 claims 2
- 230000008673 vomiting Effects 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78951406P | 2006-04-05 | 2006-04-05 | |
| US60/789,514 | 2006-04-05 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009504270A Division JP5155998B2 (ja) | 2006-04-05 | 2007-04-04 | 薬学的処方物：８−［｛１−（３，５−ビス−（トリフルオロメチル）フェニル）−エトキシ｝−メチル］−８−フェニル−１，７−ジアザ−スピロ［４．５］デカン−２−オンの塩およびそれを使用した処置方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012268500A Division JP5640065B2 (ja) | 2006-04-05 | 2012-12-07 | 薬学的処方物：８−［｛１−（３，５−ビス−（トリフルオロメチル）フェニル）−エトキシ｝−メチル］−８−フェニル−１，７−ジアザ−スピロ［４．５］デカン−２−オンの塩およびそれを使用した処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012167125A JP2012167125A (ja) | 2012-09-06 |
| JP2012167125A5 true JP2012167125A5 (OSRAM) | 2013-01-31 |
| JP5415587B2 JP5415587B2 (ja) | 2014-02-12 |
Family
ID=38441502
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009504270A Expired - Fee Related JP5155998B2 (ja) | 2006-04-05 | 2007-04-04 | 薬学的処方物：８−［｛１−（３，５−ビス−（トリフルオロメチル）フェニル）−エトキシ｝−メチル］−８−フェニル−１，７−ジアザ−スピロ［４．５］デカン−２−オンの塩およびそれを使用した処置方法 |
| JP2012131109A Expired - Fee Related JP5415587B2 (ja) | 2006-04-05 | 2012-06-08 | 薬学的処方物：８−［｛１−（３，５−ビス−（トリフルオロメチル）フェニル）−エトキシ｝−メチル］−８−フェニル−１，７−ジアザ−スピロ［４．５］デカン−２−オンの塩およびそれを使用した処置方法 |
| JP2012268500A Expired - Fee Related JP5640065B2 (ja) | 2006-04-05 | 2012-12-07 | 薬学的処方物：８−［｛１−（３，５−ビス−（トリフルオロメチル）フェニル）−エトキシ｝−メチル］−８−フェニル−１，７−ジアザ−スピロ［４．５］デカン−２−オンの塩およびそれを使用した処置方法 |
| JP2014218278A Expired - Fee Related JP6035305B2 (ja) | 2006-04-05 | 2014-10-27 | 薬学的処方物：８−［｛１−（３，５−ビス−（トリフルオロメチル）フェニル）−エトキシ｝−メチル］−８−フェニル−１，７−ジアザ−スピロ［４．５］デカン−２−オンの塩およびそれを使用した処置方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009504270A Expired - Fee Related JP5155998B2 (ja) | 2006-04-05 | 2007-04-04 | 薬学的処方物：８−［｛１−（３，５−ビス−（トリフルオロメチル）フェニル）−エトキシ｝−メチル］−８−フェニル−１，７−ジアザ−スピロ［４．５］デカン−２−オンの塩およびそれを使用した処置方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012268500A Expired - Fee Related JP5640065B2 (ja) | 2006-04-05 | 2012-12-07 | 薬学的処方物：８−［｛１−（３，５−ビス−（トリフルオロメチル）フェニル）−エトキシ｝−メチル］−８−フェニル−１，７−ジアザ−スピロ［４．５］デカン−２−オンの塩およびそれを使用した処置方法 |
| JP2014218278A Expired - Fee Related JP6035305B2 (ja) | 2006-04-05 | 2014-10-27 | 薬学的処方物：８−［｛１−（３，５−ビス−（トリフルオロメチル）フェニル）−エトキシ｝−メチル］−８−フェニル−１，７−ジアザ−スピロ［４．５］デカン−２−オンの塩およびそれを使用した処置方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US7563801B2 (OSRAM) |
| EP (2) | EP2997964A1 (OSRAM) |
| JP (4) | JP5155998B2 (OSRAM) |
| KR (1) | KR20080108319A (OSRAM) |
| CN (2) | CN103751186B (OSRAM) |
| AR (1) | AR060303A1 (OSRAM) |
| AU (1) | AU2007233389C1 (OSRAM) |
| BR (1) | BRPI0710577A2 (OSRAM) |
| CA (2) | CA2648640C (OSRAM) |
| CL (1) | CL2007000945A1 (OSRAM) |
| ES (1) | ES2553805T3 (OSRAM) |
| MX (1) | MX2008012936A (OSRAM) |
| NO (1) | NO342810B1 (OSRAM) |
| NZ (1) | NZ571693A (OSRAM) |
| PE (2) | PE20080054A1 (OSRAM) |
| SG (1) | SG10201500028RA (OSRAM) |
| TW (1) | TWI332836B (OSRAM) |
| WO (1) | WO2007114921A2 (OSRAM) |
| ZA (1) | ZA200808465B (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20030762A1 (es) | 2001-12-18 | 2003-09-05 | Schering Corp | Compuestos heterociclicos como antagonistas nk1 |
| CN102276606B (zh) | 2006-04-05 | 2013-06-12 | 欧科生医股份有限公司 | 8-[{1-(3,5-双-(三氟甲基)苯基)-乙氧基}-甲基]-8-苯基-1,7-二氮杂-螺[4.5]癸-2-酮的甲苯磺酸盐及其制备方法 |
| CL2007000945A1 (es) * | 2006-04-05 | 2008-01-25 | Schering Corp | Formulacion farmaceutica que comprende una sal cristalina de monohidrato de hidrocloruro de (5s,8s)-8-[[(1r)-1-(3,5-bistrifluorometil)fenil]-etoximetil]-8-fenil-1,7-diaza-espiro[4.5]decan-2-ona; capsula que la contiene; y uso en el tratamiento de la emesis y nausea. |
| PE20081891A1 (es) | 2007-03-22 | 2008-12-27 | Opko Health Inc | Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas |
| AR066191A1 (es) | 2007-03-22 | 2009-08-05 | Schering Corp | Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona |
| AU2009289598B2 (en) | 2008-09-05 | 2014-09-11 | Opko Health, Inc. | Process and intermediates for the synthesis of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl) -ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds |
| WO2010077669A2 (en) * | 2008-12-08 | 2010-07-08 | Teva Pharmaceutical Industries Ltd. | Palonosetron formulation |
| MX336071B (es) * | 2009-08-14 | 2016-01-06 | Opko Health Inc | Formulaciones intravenosas de antagonistas de neurocinina 1. |
| EP3002005A1 (en) | 2014-09-30 | 2016-04-06 | Molkerei Meggle Wasserburg GmbH & Co. Kg | Direct compression excipient based on lactose, cellulose and starch |
| CN104473887A (zh) * | 2014-11-12 | 2015-04-01 | 广东东阳光药业有限公司 | 一种提高利伐沙班片溶出曲线重现性的方法 |
| CN106866669A (zh) * | 2017-04-19 | 2017-06-20 | 成都百特万合医药科技有限公司 | 一种合成罗拉吡坦中间体的方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US431003A (en) * | 1890-06-24 | Store-service apparatus | ||
| GB1605190A (en) * | 1968-08-23 | 1983-03-23 | Phillips Petroleum Co | Armour plate |
| US4013613A (en) * | 1971-10-01 | 1977-03-22 | General Electric Company | Reinforced intercrystalline thermoplastic polyester compositions |
| US4079161A (en) * | 1974-07-12 | 1978-03-14 | Phillips Petroleum Company | Transparent oriented polyolefin laminated armor structure |
| FR2678971B1 (fr) * | 1991-07-08 | 1998-04-10 | Andre Giraud | Elements de structure composite transparents et leurs procedes de fabrication. |
| US5830548A (en) * | 1992-08-11 | 1998-11-03 | E. Khashoggi Industries, Llc | Articles of manufacture and methods for manufacturing laminate structures including inorganically filled sheets |
| US5665450A (en) * | 1992-08-21 | 1997-09-09 | The Curators Of The University Of Missouri | Optically transparent composite material and process for preparing same |
| JPH08502510A (ja) | 1992-10-28 | 1996-03-19 | メルク シヤープ エンド ドーム リミテツド | タキキニン拮抗剤としてのアリールメチルオキシメチルピペリジン |
| US5661162A (en) | 1992-12-14 | 1997-08-26 | Merck Sharp & Dohme Limited | 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperdines as tachykinin receptor antagonists |
| US5760018A (en) | 1994-01-13 | 1998-06-02 | Merck Sharp & Dohme Ltd. | Gem-disubstituted azacyclic tachykinin antagonists |
| US5733659A (en) * | 1995-02-27 | 1998-03-31 | Mitsubishi Engineering-Plastics Corporation | Transparent rigid resin molded product and process for producing the same |
| NZ302926A (en) * | 1995-02-28 | 1998-10-28 | Hoechst Marion Roussel Inc | Composition for use as antihistamines comprising piperidinoalkanol derivatives and inert ingredients |
| DE69616367T2 (de) | 1995-08-28 | 2002-06-27 | Schering Corp., Kenilworth | Kombinationstherapie für fortgeschrittenes krebsstadium mit temozolomid und cisplatin |
| US5759658A (en) * | 1996-04-26 | 1998-06-02 | Tables International Corporation | Composite panels, articles incorporating same and method |
| US5939098A (en) | 1996-09-19 | 1999-08-17 | Schering Corporation | Cancer treatment with temozolomide |
| US6630231B2 (en) * | 1999-02-05 | 2003-10-07 | 3M Innovative Properties Company | Composite articles reinforced with highly oriented microfibers |
| DE60024243T2 (de) * | 1999-03-30 | 2006-08-17 | Schering Corp. | Verbesserte krebsbehandlung mit temozolomid |
| US6499984B1 (en) * | 2000-05-22 | 2002-12-31 | Warner-Lambert Company | Continuous production of pharmaceutical granulation |
| DE10053151A1 (de) * | 2000-10-26 | 2002-05-08 | Bayer Ag | Zusammensetzung enthaltend thermoplastische Kunststoffe |
| WO2003042173A1 (en) | 2001-11-13 | 2003-05-22 | Schering Corporation | Nk1 antagonists |
| PE20030762A1 (es) | 2001-12-18 | 2003-09-05 | Schering Corp | Compuestos heterociclicos como antagonistas nk1 |
| US6818306B2 (en) * | 2002-09-27 | 2004-11-16 | The Boeing Company | Optically clear structural laminate |
| AU2004278158B2 (en) * | 2003-10-03 | 2009-08-13 | Pfizer Inc. | Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflammation |
| US6889938B1 (en) * | 2003-10-21 | 2005-05-10 | The Boeing Company | Structural cockpit window and method of making same |
| AU2004308935A1 (en) * | 2003-12-22 | 2005-07-14 | Schering Corporation | Pharmaceutical compositions |
| KR101228282B1 (ko) | 2004-07-01 | 2013-01-31 | 옵코 헬스, 인크. | Ｎｋ1 길항제로서의 피페리딘 유도체 |
| EP1830845A2 (en) | 2004-11-09 | 2007-09-12 | Shering Corporation | Improved dosing regimen of temozolomide for treating cancer based on the patient's mgmt level |
| CN102276606B (zh) | 2006-04-05 | 2013-06-12 | 欧科生医股份有限公司 | 8-[{1-(3,5-双-(三氟甲基)苯基)-乙氧基}-甲基]-8-苯基-1,7-二氮杂-螺[4.5]癸-2-酮的甲苯磺酸盐及其制备方法 |
| CL2007000945A1 (es) * | 2006-04-05 | 2008-01-25 | Schering Corp | Formulacion farmaceutica que comprende una sal cristalina de monohidrato de hidrocloruro de (5s,8s)-8-[[(1r)-1-(3,5-bistrifluorometil)fenil]-etoximetil]-8-fenil-1,7-diaza-espiro[4.5]decan-2-ona; capsula que la contiene; y uso en el tratamiento de la emesis y nausea. |
| AR066191A1 (es) | 2007-03-22 | 2009-08-05 | Schering Corp | Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona |
| PE20081891A1 (es) | 2007-03-22 | 2008-12-27 | Opko Health Inc | Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas |
| AU2009289598B2 (en) | 2008-09-05 | 2014-09-11 | Opko Health, Inc. | Process and intermediates for the synthesis of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl) -ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds |
| MX336071B (es) | 2009-08-14 | 2016-01-06 | Opko Health Inc | Formulaciones intravenosas de antagonistas de neurocinina 1. |
-
2007
- 2007-04-04 CL CL2007000945A patent/CL2007000945A1/es unknown
- 2007-04-04 JP JP2009504270A patent/JP5155998B2/ja not_active Expired - Fee Related
- 2007-04-04 CA CA2648640A patent/CA2648640C/en active Active
- 2007-04-04 SG SG10201500028RA patent/SG10201500028RA/en unknown
- 2007-04-04 US US11/732,663 patent/US7563801B2/en active Active
- 2007-04-04 CA CA2861281A patent/CA2861281A1/en not_active Abandoned
- 2007-04-04 AR ARP070101440A patent/AR060303A1/es unknown
- 2007-04-04 PE PE2007000412A patent/PE20080054A1/es active IP Right Grant
- 2007-04-04 KR KR1020087026488A patent/KR20080108319A/ko not_active Withdrawn
- 2007-04-04 MX MX2008012936A patent/MX2008012936A/es active IP Right Grant
- 2007-04-04 CN CN201310495198.0A patent/CN103751186B/zh not_active Expired - Fee Related
- 2007-04-04 BR BRPI0710577-0A patent/BRPI0710577A2/pt not_active Application Discontinuation
- 2007-04-04 EP EP15176475.0A patent/EP2997964A1/en not_active Withdrawn
- 2007-04-04 AU AU2007233389A patent/AU2007233389C1/en not_active Ceased
- 2007-04-04 EP EP07774641.0A patent/EP2004148B1/en not_active Not-in-force
- 2007-04-04 TW TW096112177A patent/TWI332836B/zh not_active IP Right Cessation
- 2007-04-04 NZ NZ571693A patent/NZ571693A/en not_active IP Right Cessation
- 2007-04-04 CN CN2007800206407A patent/CN101460151B/zh not_active Expired - Fee Related
- 2007-04-04 WO PCT/US2007/008345 patent/WO2007114921A2/en not_active Ceased
- 2007-04-04 ES ES07774641.0T patent/ES2553805T3/es active Active
- 2007-04-04 PE PE2011001528A patent/PE20120254A1/es not_active Application Discontinuation
-
2008
- 2008-10-03 ZA ZA2008/08465A patent/ZA200808465B/en unknown
- 2008-11-04 NO NO20084660A patent/NO342810B1/no not_active IP Right Cessation
-
2009
- 2009-06-18 US US12/487,263 patent/US7981905B2/en active Active
-
2011
- 2011-07-18 US US13/184,926 patent/US8404702B2/en active Active
-
2012
- 2012-06-08 JP JP2012131109A patent/JP5415587B2/ja not_active Expired - Fee Related
- 2012-12-07 JP JP2012268500A patent/JP5640065B2/ja not_active Expired - Fee Related
-
2013
- 2013-03-19 US US13/847,242 patent/US9345692B2/en active Active
-
2014
- 2014-10-27 JP JP2014218278A patent/JP6035305B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012167125A5 (OSRAM) | ||
| JP5349059B2 (ja) | 薬物の組み合わせを投与するための剤形 | |
| AU2010320598B2 (en) | Compositions for treating centrally mediated nausea and vomiting | |
| JP2013511507A5 (OSRAM) | ||
| JP2013522373A5 (OSRAM) | ||
| WO2011107855A3 (en) | Sustained release oral liquid suspension dosage form | |
| NZ753904A (en) | Compositions and methods for treating anemia | |
| PH12015502134A1 (en) | Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration | |
| JP2009545560A5 (OSRAM) | ||
| JP2015523407A5 (OSRAM) | ||
| JP2012255026A5 (OSRAM) | ||
| HRP20201316T1 (hr) | Novi modulatori receptora sfingozin-fosfata | |
| JP2012505884A5 (OSRAM) | ||
| JP2012193216A5 (OSRAM) | ||
| EP2841061A1 (en) | Methods for treating cardiovascular disorder | |
| CA2802093A1 (en) | Combination therapy with lisdexamphetamine and extended release guanfacine | |
| JP2013516493A5 (OSRAM) | ||
| JP2015508082A5 (OSRAM) | ||
| NZ611026A (en) | Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria | |
| WO2007145863A3 (en) | Sustained release formulation of naltrexone | |
| ES2620078T3 (es) | Formulación oral para el tratamiento de enfermedades cardiovasculares | |
| US20150290174A1 (en) | Pharmaceutical formulations and method of using the same for alleviating symptoms of hangover, stomach flu or migraine | |
| RU2011113733A (ru) | Производные 1-амино-алкилциклогексана для лечения когнитивного нарушения при шуме в ушах | |
| WO2014096982A1 (en) | Stable pharmaceutical compositions of saxagliptin or salts thereof | |
| JP2012041314A5 (OSRAM) |